The future of these 7 biotechs hinges on their ability to treat a silent liver disease and capture a $9.6 billion market. Here's exactly what investors should be watching for this year.

The future of these 7 biotechs hinges on their ability to treat a silent liver disease and capture a $9.6 billion market. Here's exactly what investors should be watching for this year.

Business Insider

Published

· There are about 70 drugs in clinical testing for NASH, a fatty liver disease that affects millions of Americans and is a top cause of liver transplants.
· We identified seven biotechs that have staked their companies — and their stocks — on finding success in NASH in 2020.
· Those seven are: Intercept Pharmaceuticals,...

Full Article